Aileron Therapeutics, Inc. Quarterly Operating Income (Loss) in USD from Q1 2016 to Q3 2024

Taxonomy & unit
us-gaap: USD
Description
The net result for the period of deducting operating expenses from operating revenues.
Summary
Aileron Therapeutics, Inc. quarterly/annual Operating Income (Loss) history and growth rate from Q1 2016 to Q3 2024.
  • Aileron Therapeutics, Inc. Operating Income (Loss) for the quarter ending September 30, 2024 was -$6.07M, a 206% decline year-over-year.
  • Aileron Therapeutics, Inc. Operating Income (Loss) for the twelve months ending September 30, 2024 was -$29.6M, a 116% decline year-over-year.
  • Aileron Therapeutics, Inc. annual Operating Income (Loss) for 2023 was -$16.3M, a 41.1% increase from 2022.
  • Aileron Therapeutics, Inc. annual Operating Income (Loss) for 2022 was -$27.6M, a 3.92% decline from 2021.
  • Aileron Therapeutics, Inc. annual Operating Income (Loss) for 2021 was -$26.6M, a 29.8% decline from 2020.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Quarterly (USD)
Operating Income (Loss), YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2024 -$29.6M -$6.07M -$4.09M -206% Jul 1, 2024 Sep 30, 2024 10-Q 2024-11-14
Q2 2024 -$25.5M -$9.04M -$7.05M -354% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-14
Q1 2024 -$18.5M -$7.21M -$2.19M -43.8% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-15
Q4 2023 -$16.3M -$7.29M -$2.59M -55% Oct 1, 2023 Dec 31, 2023 10-K 2024-04-15
Q3 2023 -$13.7M -$1.98M +$4.5M +69.4% Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-14
Q2 2023 -$18.2M -$1.99M +$6.05M +75.2% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-14
Q1 2023 -$24.2M -$5.01M +$3.41M +40.5% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-15
Q4 2022 -$27.6M -$4.7M +$2.11M +31% Oct 1, 2022 Dec 31, 2022 10-K 2024-04-15
Q3 2022 -$29.8M -$6.48M +$309K +4.55% Jul 1, 2022 Sep 30, 2022 10-Q 2023-10-13
Q2 2022 -$30.1M -$8.04M -$2.03M -33.8% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-11
Q1 2022 -$28M -$8.42M -$1.43M -20.5% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-08
Q4 2021 -$26.6M -$6.82M -$2.62M -62.6% Oct 1, 2021 Dec 31, 2021 10-K 2023-03-20
Q3 2021 -$24M -$6.79M -$1.76M -35.1% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-01
Q2 2021 -$22.2M -$6.01M -$1.61M -36.6% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-15
Q1 2021 -$20.6M -$6.99M -$113K -1.64% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-05
Q4 2020 -$20.5M -$4.19M +$3.16M +43% Oct 1, 2020 Dec 31, 2020 10-K 2021-03-24
Q3 2020 -$23.7M -$5.03M +$2.89M +36.5% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-12
Q2 2020 -$26.5M -$4.4M +$2.98M +40.4% Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-11
Q1 2020 -$29.5M -$6.88M +$437K +5.98% Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-11
Q4 2019 -$30M -$7.35M -$366K -5.24% Oct 1, 2019 Dec 31, 2019 10-K 2021-03-24
Q3 2019 -$29.6M -$7.92M -$417K -5.56% Jul 1, 2019 Sep 30, 2019 10-K 2021-03-24
Q2 2019 -$29.2M -$7.38M +$2.28M +23.6% Apr 1, 2019 Jun 30, 2019 10-K 2021-03-24
Q1 2019 -$31.5M -$7.31M +$450K +5.8% Jan 1, 2019 Mar 31, 2019 10-K 2021-03-24
Q4 2018 -$31.9M -$6.98M +$59K +0.84% Oct 1, 2018 Dec 31, 2018 10-K 2020-03-30
Q3 2018 -$32M -$7.5M -$1.07M -16.7% Jul 1, 2018 Sep 30, 2018 10-K 2020-03-30
Q2 2018 -$30.9M -$9.66M -$4.71M -95.1% Apr 1, 2018 Jun 30, 2018 10-K 2020-03-30
Q1 2018 -$26.2M -$7.76M -$3.17M -69.2% Jan 1, 2018 Mar 31, 2018 10-K 2020-03-30
Q4 2017 -$23M -$7.04M -$2.59M -58.3% Oct 1, 2017 Dec 31, 2017 10-K 2019-03-29
Q3 2017 -$20.4M -$6.43M -$2.19M -51.8% Jul 1, 2017 Sep 30, 2017 10-K 2019-03-29
Q2 2017 -$18.2M -$4.95M +$598K +10.8% Apr 1, 2017 Jun 30, 2017 10-K 2019-03-29
Q1 2017 -$18.8M -$4.59M -$650K -16.5% Jan 1, 2017 Mar 31, 2017 10-K 2019-03-29
Q4 2016 -$18.2M -$4.45M Oct 1, 2016 Dec 31, 2016 10-K 2018-04-02
Q3 2016 -$4.23M Jul 1, 2016 Sep 30, 2016 10-K 2018-04-02
Q2 2016 -$5.55M Apr 1, 2016 Jun 30, 2016 10-K 2018-04-02
Q1 2016 -$3.94M Jan 1, 2016 Mar 31, 2016 10-K 2018-04-02
* An asterisk sign (*) next to the value indicates that the value is likely invalid.